Cargando…

Prostacyclin and thromboxane in benign and malignant breast tumours.

6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic...

Descripción completa

Detalles Bibliográficos
Autores principales: Laekeman, G. M., Vergote, I. B., Keersmaekers, G. M., Heiremans, J., Haensch, C. F., de Roy, G., Uyttenbroeck, F. L., Herman, A. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001625/
https://www.ncbi.nlm.nih.gov/pubmed/3530307
_version_ 1782135643050082304
author Laekeman, G. M.
Vergote, I. B.
Keersmaekers, G. M.
Heiremans, J.
Haensch, C. F.
de Roy, G.
Uyttenbroeck, F. L.
Herman, A. G.
author_facet Laekeman, G. M.
Vergote, I. B.
Keersmaekers, G. M.
Heiremans, J.
Haensch, C. F.
de Roy, G.
Uyttenbroeck, F. L.
Herman, A. G.
author_sort Laekeman, G. M.
collection PubMed
description 6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-disease tissues (P less than 0.05). The 6-keto-PGF1 alpha/TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P less than 0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1 alpha/TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1 alpha/TXB2 ratios (P = 0.01) whereas the latter value was higher when infiltration was lower (P = 0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1 alpha/TXB2 ratio (P = 0.04). Cumulation of variables revealed lower prostanoid ratios in tumours greater than 2 cm without lymph node metastasis then tumours less than 2 cm with lymph node metastasis (P = 0.04). A first follow-up (14 months) showed a higher 6-keto-PGF1 alpha/TXB2 ratio in patients who developed metastasis (P = 0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer.
format Text
id pubmed-2001625
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20016252009-09-10 Prostacyclin and thromboxane in benign and malignant breast tumours. Laekeman, G. M. Vergote, I. B. Keersmaekers, G. M. Heiremans, J. Haensch, C. F. de Roy, G. Uyttenbroeck, F. L. Herman, A. G. Br J Cancer Research Article 6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-disease tissues (P less than 0.05). The 6-keto-PGF1 alpha/TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P less than 0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1 alpha/TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1 alpha/TXB2 ratios (P = 0.01) whereas the latter value was higher when infiltration was lower (P = 0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1 alpha/TXB2 ratio (P = 0.04). Cumulation of variables revealed lower prostanoid ratios in tumours greater than 2 cm without lymph node metastasis then tumours less than 2 cm with lymph node metastasis (P = 0.04). A first follow-up (14 months) showed a higher 6-keto-PGF1 alpha/TXB2 ratio in patients who developed metastasis (P = 0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer. Nature Publishing Group 1986-09 /pmc/articles/PMC2001625/ /pubmed/3530307 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Laekeman, G. M.
Vergote, I. B.
Keersmaekers, G. M.
Heiremans, J.
Haensch, C. F.
de Roy, G.
Uyttenbroeck, F. L.
Herman, A. G.
Prostacyclin and thromboxane in benign and malignant breast tumours.
title Prostacyclin and thromboxane in benign and malignant breast tumours.
title_full Prostacyclin and thromboxane in benign and malignant breast tumours.
title_fullStr Prostacyclin and thromboxane in benign and malignant breast tumours.
title_full_unstemmed Prostacyclin and thromboxane in benign and malignant breast tumours.
title_short Prostacyclin and thromboxane in benign and malignant breast tumours.
title_sort prostacyclin and thromboxane in benign and malignant breast tumours.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001625/
https://www.ncbi.nlm.nih.gov/pubmed/3530307
work_keys_str_mv AT laekemangm prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT vergoteib prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT keersmaekersgm prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT heiremansj prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT haenschcf prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT deroyg prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT uyttenbroeckfl prostacyclinandthromboxaneinbenignandmalignantbreasttumours
AT hermanag prostacyclinandthromboxaneinbenignandmalignantbreasttumours